Several studies have demonstrated that pharmacological targeting of RUVBL1/2 can extend the survival of tumor-bearing mice, although the mechanisms that underlie a tumor-specific dependence on RUVBL1/2 ATPase activity are unclear49,51,52,76. The gene discussed is DNAH8; the disease is neoplasm.